

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

KP-N-YN

RRID:CVCL_1341

Type: Cell Line

Proper Citation

JCRB Cat# IFO50431, RRID:CVCL_1341

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1341

Proper Citation: JCRB Cat# IFO50431, RRID:CVCL_1341

Description: Cell line KP-N-YN is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adrenal gland neuroblastoma

Defining Citation: [PMID:2019470](#), [PMID:12702577](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23268333](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KP-N-YN

Synonyms: KPNYN, Kyoto Pediatrics-Neuroblastoma-YN

Cross References: BTO:BTO_0003546, CLO:CLO_0037079, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:610, BioSample:SAMN03470961, BioSample:SAMN10988113, cancercellines:CVCL_1341, Cell_Model_Passport:SIDM00556, CGH-DB:80-1, CGH-DB:9082-4, ChEMBL-Cells:ChEMBL3308265, ChEMBL-Targets:ChEMBL2366280, Cosmic:907314, Cosmic-CLP:907314, DepMap:ACH-000227, EGA:EGAS00001000978, GDSC:907314, GEO:GSM887241, GEO:GSM888315, GEO:GSM1670007, IARC_TP53:21442, JCRB:IFO50431, LiGeA:CCLE_699, LINCS_LDP:LCL-1985,

PharmacDB:KPNYN_788_2019, PRIDE:PXD030304, Progenetix:CVCL_1341, PubChem_Cell_line:CVCL_1341, Wikidata:Q54900402

ID: CVCL_1341

Vendor: JCRB

Catalog Number: IFO50431

Record Creation Time: 20220427T220708+0000

Record Last Update: 20260815T234428+0000

Ratings and Alerts

No rating or validation information has been found for KP-N-YN.

No alerts have been found for KP-N-YN.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T??cell therapeutics. Immunity, 57(12), 2945.

Li X, et al. (2023) YM155 inhibits neuroblastoma growth through degradation of MYCN: A new role as a USP7 inhibitor. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 181, 106343.